Melanoma Diagnostics
DermTech to Cut 15 Percent of Workforce in Restructuring to Focus on Skin Cancer Test
The San Diego-based company said it will halt its pipeline programs in order to focus on growing volume and reimbursement for its noninvasive melanoma DNA test.
Castle Biosciences Q1 Revenues Grow 18 Percent
The Friendswood, Texas-based molecular diagnostics company reported revenues of $26.9 million in Q1 2022, up from $22.8 million a year ago.
Castle Biosciences Q4 Revenues Grow 45 Percent
The molecular diagnostics company said it delivered 33 percent more DecisionDx-Melanoma test results in Q4 2021 than in the previous year's fourth quarter.
Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test
The gene expression profile assay is meant to aid dermatopathologists in characterizing difficult-to-diagnose melanocytic lesions.
Castle Biosciences Awarded VA Supply Contract for Melanoma Test
The company said the contract will provide greater access to its DecisionDx-Melanoma gene expression profile test for veterans and active duty military.